Ricasetron: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'Watchedfields') per Chem/infobox_drug validation (report [[Wikipedia talk:WikiProject_Pharmacology|erro... |
|||
| Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = 451220265 |
| verifiedrevid = 451220265 |
||
| IUPAC_name = ''endo''-''N''-(8-Methyl-8-azabicyclo[3.2.1]oct-3yl)-2,3-dihydro-3,3-dimethyl-indole-1-carboxamide |
| IUPAC_name = ''endo''-''N''-(8-Methyl-8-azabicyclo[3.2.1]oct-3yl)-2,3-dihydro-3,3-dimethyl-indole-1-carboxamide |
||
| Line 36: | Line 37: | ||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = R92JB88O88 |
| UNII = R92JB88O88 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| ChemSpiderID = 16736765 |
| ChemSpiderID = 16736765 |
||
| Line 42: | Line 44: | ||
| molecular_weight = 313.436 g/mol |
| molecular_weight = 313.436 g/mol |
||
| smiles = CC1(CN(c2c1cccc2)C(=O)N[C@H]3C[C@H]4CC[C@@H](C3)N4C)C |
| smiles = CC1(CN(c2c1cccc2)C(=O)N[C@H]3C[C@H]4CC[C@@H](C3)N4C)C |
||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChI = 1S/C19H27N3O/c1-19(2)12-22(17-7-5-4-6-16(17)19)18(23)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,13-15H,8-12H2,1-3H3,(H,20,23)/t13-,14+,15- |
| StdInChI = 1S/C19H27N3O/c1-19(2)12-22(17-7-5-4-6-16(17)19)18(23)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,13-15H,8-12H2,1-3H3,(H,20,23)/t13-,14+,15- |
||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChIKey = ILXWRFDRNAKTDD-QDMKHBRRSA-N |
| StdInChIKey = ILXWRFDRNAKTDD-QDMKHBRRSA-N |
||
}} |
}} |
||
Revision as of 00:03, 12 August 2016
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H27N3O |
| Molar mass | 313.436 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Ricasetron (BRL-46470) is a drug which acts as a selective antagonist at the serotonin 5-HT3 receptor.[1] It has antiemetic effects as with other 5-HT3 antagonists,[2] and also has anxiolytic effects significantly stronger than other related drugs,[3] and with less side effects than benzodiazepine anxiolytics.[4][5] However, it has never been developed for medical use.
See also
References
- ^ Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA (August 1993). "BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors". Neuropharmacology. 32 (8): 729–35. doi:10.1016/0028-3908(93)90180-B. PMID 8413836.
- ^ Bermudez J, Sanger GJ (June 1994). "Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets". The Journal of Pharmacy and Pharmacology. 46 (6): 520–1. doi:10.1111/j.2042-7158.1994.tb03843.x. PMID 7932054.
- ^ Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N, Wood MD (1993). "BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties". Psychopharmacology. 110 (3): 257–64. doi:10.1007/BF02251279. PMID 7831418.
- ^ Link CG, Leigh TJ, Dennison JK (April 1993). "The effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG". British Journal of Clinical Pharmacology. 35 (4): 395–9. doi:10.1111/j.1365-2125.1993.tb04156.x. PMC 1381550. PMID 8485019.
- ^ de Souza Silva M, Guimarães FS, Graeff FG, Tomaz C (December 1993). "Absence of amnestic effect of an anxiolytic 5-HT3 antagonist (BRL 46470A) injected into basolateral amygdala, as opposed to diazepam". Behavioural Brain Research. 59 (1–2): 141–5. doi:10.1016/0166-4328(93)90160-R. PMID 8155281.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |